title: [Multiple myeloma--new therapeutic perspectives].
abstract: This article contains the data related to diagnosis and treatment of multiple myeloma from several bone marrow transplantation centers. High-dose chemotherapy with stem cell transplantation is currently the best way of treatment in patients with multiple myeloma. The risk factors are chromosomal aberrations, high level of beta-2-microglobulin, CRP and LDH serum levels. The optimal source of stem cells is the blood because of financial and hematological reasons.
authors.affiliation: Kliniki Hematologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie. alekskot@endo.cm-uj.krakow.pl
authors.forename: A B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: T
authors.initials: T
authors.lastname: Wolska-Smoleń
authors.forename: A
authors.initials: A
authors.lastname: Jurczyszyn
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase